Ottobock and Bioness Inc. have announced a partnership to expand distribution and access of their functional electrical stimulation devices in the European Union, the United Kingdom, Switzerland, Norway, Turkey and India, according to a press release.
“Our partnership with Ottobock opens up significant opportunity for both organizations,” Todd Cushman, president and chief executive officer of Bioness, said in the release. “Our leading technology position in functional electrical stimulation, highlighted by the recent clearance of the L300 Go System by U.S. FDA and CE Mark, combined with Ottobock’s resources, reputation and market reach, creates an extremely powerful synergy.”
Ottobock will begin product commercialization within its orthotics division starting in September, and distribute Bioness’ line of functional electrical stimulation devices for both the lower and upper extremities, the release noted. According to both companies, the partnership will allow Ottobock and Bioness to improve technology access as well as enhance the healthcare provider and patient experience.
“Since 2005, Ottobock has been offering functional electrical stimulation device solutions as part of their mobility after stroke concept for healthcare providers and patients,” Frank Bömers, global head of orthotics for Ottobock, said in the release. “Our strategic partnership with Bioness reinforces our commitment to the technology platform and allows Ottobock to leverage our resources to expand product access and affordability.”